CYTX : Analysis & Opinions
November 17, 2016Cytori Therapeutics continues to bolster its IP portfolio after receiving new drug patents in the US and Europe.
November 15, 2016Cytori Therapeutics secured orphan drug status for its ECCS-50 drug to treat scleroderma.
November 11, 2016Cytori posted a 3Q loss and revenue below analyst estimates.
September 23, 2016The renewed contract option indicates on-track progress of Cytori Cell Therapy, along with increased valuations.